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b-Cell Mass and Turnover in Humans
Effects of obesity and aging
YOSHIFUMI SAISHO, MD1
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DAVID ELASHOFF, PHD2
ROBERT A. RIZZA, MD3
PETER C. BUTLER, MD1
OBJECTIVEdWe sought to establish b-cell mass, b-cell apoptosis, and b-cell replication in
humans in response to obesity and advanced age.
RESEARCH DESIGN ANDMETHODSdWe examined human autopsy pancreas from
167 nondiabetic individuals 20–102 years of age. The effect of obesity on b-cell mass was
examined in 53 lean and 61 obese subjects, and the effect of aging was examined in 106 lean
subjects.
RESULTSdb-Cell mass is increased by;50%with obesity (from 0.8 to 1.2 g).With advanced
aging, the exocrine pancreas undergoes atrophy butb-cell mass is remarkably preserved. There is
minimal b-cell replication or apoptosis in lean humans throughout life with no detectable
changes with obesity or advanced age.
CONCLUSIONSdb-Cell mass in human obesity increases by;50% by an increase in b-cell
number, the source of which is unknown. b-Cell mass is well preserved in humans with ad-
vanced aging.
Diabetes Care 36:111–117, 2013
The incidence of type 2 diabetes in-creases with obesity and aging (1).There is a deficit in b-cell mass
with increased b-cell apoptosis in type 2
diabetes (2). Although there are numer-
ous studies of changes in b-cell mass and
turnover in rodents, inevitably the data is
much more limited in humans. As there is
an increasing appreciation that regulation
of b-cell mass in humans and rodents can
be quite different, additional studies in
humans, where possible, is important.
In the current study, we addressed the
following questions.
First, is b-cell mass adaptively in-
creased in obese humans, and if so, is this
through increased b-cell replication as
widely reported in rodents? It has been re-
ported that b-cell mass increases with obe-
sity in age-matched individuals but b-cell
replication was not reported (3). Second, is
b-cell apoptosis increased with obesity?
The increased b-cell apoptosis in type 2 di-
abetes (2) has been ascribed to lipotoxicity,
based on increased b-cell apoptosis in ro-
dents with obesity due to deficient leptin
signaling (4). Since the relative fat content
(fat-to-acinar ratio) accumulates in the pan-
creas in humans with obesity (5), if this is
sufficient to induce increased b-cell apo-
ptosis, then it would be anticipated that
humans with marked obesity would have
increased b-cell apoptosis.
Third, we questioned if b-cell mass
adaptively decreases with aging, and if so,
is this due to increased b-cell apoptosis?
b-Cell function declines in humans with
aging (6). The exocrine pancreas undergoes
marked atrophy after 60 years of age, but
there is limited data available about the
changes in b-cell mass with aging, with
one study reporting a marginal decline
with age (3) but providing no measure of
b-cell turnover.
RESEARCH DESIGN AND
METHODS
Study design
Pancreas was obtained from Mayo Clinic
autopsy archives. At autopsy, the pancreas
is not routinely dissected free from retro-
peritoneal tissues to permit measurement
of pancreas weight. To address this, we
established population data for pancreas
volume from abdominal computed tomog-
raphy (CT) scans in 1,887 adults as pre-
viously reported (5) and validated (7). In
that previously reported CT scan study, the
relationship between obesity and pancreas
volume and fat content was examined in
460 lean individuals (mean BMI 22 kg/m2),
430 overweight individuals (mean BMI 27
kg/m2), and 230 obese individuals (mean
BMI 34 kg/m2), a range deliberately se-
lected to encompass the range of cases in
the current study. Also, the age range of
individuals in the CT scan study, from 20
to 100 years of age, was also selected de-
liberately to permit the development of
population data relevant to the present ag-
ing study.b-Cell mass was then computed
as a product of fractional b-cell area and
pancreas weight (assuming 1 cm3 pan-
creas = 1 g).
Subjects
University of California, Los Angeles
(UCLA), and Mayo Clinic Institutional
Review Board permission was obtained
for these studies. Potential cases were first
identified by retrospective analysis of the
Mayo Clinic autopsy database. To be
included, cases were required to have
had 1) a full autopsy within 24 h of death;
2) pancreatic tissue stored that was of ad-
equate size and quality; 3) no history of
diabetes, pancreatitis, or pancreatic sur-
gery; and 4) no use of glucocorticoids.
Cases were excluded if pancreatic tissue
had undergone autolysis. Preference was
given to cases where the final illness was
relatively short term (for example, trauma
or sudden vascular event), so as to mini-
mize the confounding effects of a pro-
longed final illness on the nutritional
status of the individual and effects this
may have had on islet morphology. Case
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subjects were identified based on these
preferences at the Mayo Clinic, and the
sections of selected case subjects were ob-
tained and made available to UCLA inves-
tigators in a manner coded to conceal the
personal identity of the subjects. The blood
glucose value was obtained from the most
recent ambulatory overnight-fasted value in
the Mayo Medical Center clinical record,
not from the final in-patient glucose values,
which are subject to confounding factors
such as premortem stress and intravenous
glucose. The characteristics of the cases are
summarized in Supplementary Table 1,
with causes of death in Supplementary Ta-
ble 2.
Lean (n = 53, BMI ,25 kg/m2) and
obese (n = 61, BMI $27 kg/m2) case sub-
jects, 20–59 years of age, were included to
evaluate the impact of obesity on b-cell
mass (Supplementary Table 1A). Although
this BMI cutoff for obesity is lower than
current definitions of obesity, the two
groups were selected with the intention of
examining the impact of insulin resistance
on b-cell mass, appreciating from available
data that the selected ranges for BMI would
have resulted in groups with contrasting
insulin sensitivity. A limitation of human
autopsy studies such as these is that insulin
sensitivity cannot be measured in the two
groups. Fasting plasma glucose (FPG) was
slightly higher in the obese subjects than
the lean subjects (P =0.05) (Supplementary
Table 1A), consistent with obesity-related
insulin resistance (8).
For the aging study, 106 case sub-
jects, 20–102 years of age, all with a BMI
,25 kg/m2, were divided by decile age-
groups (Supplementary Table 1B). Each
decile group included 9–20 subjects, the
BMI being matched between groups.
Consistent with prior reports, FPG ten-
ded to increase with age (Supplementary
Table 1B) (9,10).
Pancreatic tissue processing
At autopsy, the pancreas was resected from
the tail and, with a sample of spleen, fixed
in formaldehyde and embedded in paraffin
for subsequent analysis. Sections (5 mm)
were stained for 1) insulin (peroxidase
staining) and hematoxylin for light micros-
copy; 2) insulin, Ki67, and DAPI; and 3)
insulin, Tdt-mediateddUTPnick-end label-
ing (TUNEL), and DAPI (immunofluores-
cence), as previously described (2,11,12).
For immunohistochemical staining, the fol-
lowing primary antibodies were used:
guinea pig anti-insulin (1:100; Zymed Lab-
oratories, San Francisco, CA) and mouse
Ki67 (1:50, MIB-1; DAKO, Carpinteria,
CA). Secondary antibodies labeled with
Cy3 andfluorescein isothiocyanate (Jackson
ImmunoResearch Laboratories, West
Grove, PA) were used at a dilution of
1:100. For TUNEL staining, the in situ cell
death detection kit TMR red (Roche Diag-
nostics, Mannheim, Germany) was used.
Morphometric analysis
Allmorphometric analyseswere performed
by two independent investigators (Y.S. and
A.E.B.), and if results varied by .10% in
any individual, the analyses were per-
formed again by both investigators. The
mean of the results by the two investigators
was used. To quantify fractionalb-cell area,
the entire pancreatic section was imaged at
403magnification (43 objective). The ra-
tio of the b-cell area/total pancreas paren-
chymal area was digitally measured as
previously described (2) using Image Pro
Plus software (Media Cybernetics, Silver
Springs, MD). After pancreas fixation, pan-
creas sections retain exocrine and endo-
crine tissue but not fat, which is removed
during fixation. Therefore, the measured
fractional b-cell area is a fraction of b-cell
area to total pancreas parenchymal area.
To measure individual b-cell size and
nuclear diameter, five islets per case (i.e.,
100 islets lean vs. 100 islets obese) were
selected at random and imaged at 4003
(403 objective). b-Cell size was deter-
mined as mean individual b-cell cross-
sectional area. For the mean individual
b-cell cross-sectional area, the insulin-positive
area of each islet was divided by the num-
ber of nuclei within the insulin-positive
area. For the mean nuclear diameter, these
islets were then examined to identify five
representative b-cell nuclei each, as previ-
ously described (13,14).Once the identified
nucleus was encircled, the measurement
of 180 nuclear diameters per nucleus
was performed using Image Pro Plus,
which quantified these 180 diameters at
28 angles throughout the circumference
of the nucleus. The individual b-cell size
and nuclear diameter were also evaluated
in BMI-matched cases, five each, from
each decile (i.e., total of 200 islets from
40 cases) for the aging study.
b-Cell replication and apoptosis were
quantified in 13 obese vs. 14 lean individ-
uals. b-Cell replication and apoptosis
were also quantified in 13 elderly individ-
uals for the aging study. Since b-cell rep-
lication and apoptosis are rare in the
human pancreas, every islet in each pan-
creas section (189 6 8 islets per section)
double stained by the insulin and Ki67 or
TUNEL technique was imaged at 2003
magnification using a Leica DM6000 mi-
croscope (Leica Microsystems, Wetzlar,
Germany) and Openlab software (Impro-
vision, Waltham, MA), and b-cell replica-
tion and apoptosis were documented.
Then, the frequency of b-cell replication
and apoptosis were expressed as percent-
age of b-cells. A total of 578,452 b-cells
(6,288 6 346 b-cells per section) were
assessed for these analyses.
Pancreas parenchymal volume
To determine b-cell mass, the pancreas pa-
renchymal volume was estimated by use of
equations based on the population data de-
scribed in detail in elsewhere (5). In brief,
the pancreas parenchymal volume in-
creases in childhood to reach a plateau at
20 years of age. From 20 to 60 years of age,
pancreas parenchymal volume is stable and
is described as a function of obesity. After
60 years of age, pancreatic parenchymal
volume declines linearly, being described
as a function of age.
Assessment of b-cell mass
b-Cell mass was calculated as a product of
the fractional b-cell area determined by
immunohistochemical staining in each
individual, and the estimated pancreas
parenchymal weight as above (assuming
1 g of weight per 1 cm3 pancreas volume).
Statistical analysis
Data are presented as mean6 SEM. Statisti-
cal comparisons were carried out using the
Student t test or one-way ANOVA, with a P
value of,0.05 taken as significant. A simple
regression was carried out for the correlation
analysis. The Wilcoxon rank sum test was
performed to compare b-cell replication
and apoptosis between groups due to the
skewed distributions of the observations.
Confidence intervals for group differences
of mean b-cell turnover were constructed
to obtain ranges of likely differences.
RESULTS
b-Cell mass in obesity
The fractional b-cell/pancreas parenchy-
mal area is;30% higher in the obese com-
pared with the lean group (2.2 6 0.1 vs.
1.6 6 0.1%, P , 0.01) (Figs. 1 and 2A).
b-Cell mass is ;50% higher in the obese
compared with the lean group (1.2 6 0.1
vs. 0.86 0.04 g, P, 0.0001) (Fig. 2). Both
the fractionalb-cell area (r = 0.3, P = 0.001)
and the calculated b-cell mass (r = 0.5, P,
0.0001) (Fig. 3) are increased as a function
of BMI, although there is considerable var-
iance in b-cell mass not explained by BMI.
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b-Cell mass with obesity and aging
There is no correlation betweenb-cell mass
and FPG, although the range of the FPG is,
by design (all nondiabetic), narrow.
The mean individual b-cell cross-
sectional area is comparable in the obese
and lean groups (12564 vs. 12466mm2,
P = 0.9) (Fig. 2), implying that the increase
in b-cell mass in obesity is accomplished
by increased b-cell number rather than hy-
pertrophy. The mean b-cell nuclear diam-
eter, an indirectmarker of secretory activity,
is increased in obesity (6.96 0.2 vs. 6.06
0.2 mm, P, 0.001), consistent with prior
findings (13).
b-Cell mass with aging
The most striking change in pancreas
morphology with advanced age is atrophy
of the exocrine pancreas with relative
increasing fibrosis and fat accumulation (in-
creased fat-to-acinar ratio) (Fig. 1). However,
in contrast to the exocrine pancreas, islet
structure is relatively maintained with ad-
vanced age in human pancreas. As a result,
the fractional b-cell area increases with ad-
vanced age (r = 0.3, P, 0.01) (Fig. 4). There
is no sex difference in the fractional b-cell
area with aging (2.0 6 0.2 vs. 2.2 6 0.3%
inmales and females 60years of age andover,
P = 0.5). Despite the exocrine atrophy with
advanced age, the calculated b-cell mass re-
mained constant from 20 to 100 years of age
(Fig. 4). Although there was no significant
change in b-cell size with aging, the mean
b-cell nuclear diameter increased with age
(r = 0.6, P, 0.0001) (Fig. 4).
b-Cell replication and apoptosis
with obesity and aging
The subsets of individuals in which b-cell
turnover was evaluated were similar with
respect to age and BMI to the larger cohort.
For example, the lean young subjects stud-
ied for b-cell turnover had similar age and
BMI to the overall lean young group.b-Cell
replication was very infrequent and un-
changed by either obesity (0.021 6
0.007% in obese young group vs.
0.063 6 0.026% in lean young group,
P = 0.34, 95% CI for difference in means
[20.014 to 0.099]) or advanced age
(0.020 6 0.005% in lean old group, P =
0.24 vs. lean young group, 95% CI
[20.012 to 0.099]). Likewise, b-cell
apoptosis was also infrequently detected,
with nine events (observed in cells from
five subjects) observed out of 236,771 cells
examined. The proportion of apoptotic
b-cells was unchanged by either obesity
(0.0085 6 0.0059% in obese young
group vs. 0.0013 6 0.0013% in lean
young group, P = 0.48) or advanced age
(0.0032 6 0.0025% in lean old group,
P = 0.53 vs. lean young group).
CONCLUSIONSdA deficit in b-cell
mass with increased b-cell apoptosis is
characteristic of both type 1 and 2 diabe-
tes (2,11). Obesity and advancing age are
both risk factors for the development of
type 2 diabetes (1). However, most indi-
viduals with obesity or advanced age do
not develop type 2 diabetes. In the current
study, we sought to evaluate the changes
in b-cell mass and b-cell turnover with
obesity and aging in nondiabetic humans.
We report an;50% increase in b-cell
mass induced by obesity but with a wide
variance not explained by obesity or age
(Supplementary Fig. 2). These findings
are in broad agreement with the few studies
available in humans. Ogilvie (15) reported
that islets of Langerhans were enlarged in
humans with obesity as early as 1933.
Klöppel et al. (16) reported no increase in
fractional b-cell area but a twofold increase
in pancreas parenchymal volume in four
obese humans compared with seven lean
humans. Yoon et al. (17) reported a posi-
tive linear correlation between fractional
b-cell area and BMI in nine nondiabetic
humans with a BMI of 22–27 kg/m2 in pa-
tients undergoing partial pancreatectomy
for pancreatic tumors. We previously re-
ported an ;50% increase in fractional
b-cell area in 31 obese nondiabetic humans
compared with 17 lean nondiabetic hu-
mans, but in that study, the lean and obese
groups were not age matched as they were
Figure 1dRepresentative insulin (brown)-hematoxylin immunohistochemistry of pancreas
(original magnification 3100). Examples of lean (male, 28 years of age, BMI 23.4) (A), obese
(male, 44 years of age, BMI 33.6) (B), and elderly (male, 91 years of age, BMI 16.2; female, 100
years of age, BMI 24.9) (C and D) subjects. The fractional pancreatic insulin-positive area/
pancreas parenchymal area, average islet size, and islet density are all modestly increased in
obesity (B) compared with lean subjects (A). Pancreatic fat was also increased in obesity (B).
Whereas atrophy, fibrosis, and fat accumulation are typical in the exocrine pancreas of elderly
individuals (C and D), compared with a younger population (A), islet structure was remarkably
maintained (C and D). As a result, fractional b-cell area/pancreas parenchymal area was in-
creased in elderly vs. younger individuals (C and D vs. A). Scale bars, 200 mm. (A high-quality
digital representation of this figure is available in the online issue.)
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selected as control groups for lean and
obese individuals with type 2 diabetes.
In an autopsy study, Rahier et al. (3)
reported an increment in b-cell mass of
20% in individuals with a BMI of 26–40
kg/m2 (n = 25) compared with those
with a BMI of ,25 kg/m2 (n = 26).
Despite a variety of methodological differ-
ences, the range of measured b-cell mass
in the Rahier article and the current study
are in broad agreement. For example, in
the Rahier article, the b-cell fractional
area of the pancreas was measured by
manual point counting a quartile of sec-
tions obtained from the body and tail of
the pancreas, whereas in the current
study, the fractional b-cell area was mea-
sured in the entirety of sections from the
tail by an automated image analysis sys-
tem. Rahier et al. (3) observed marked
variance between the body and tail within
individuals not seen in a prior study (17)
or in our own studies of pancreas pro-
cured from brain-dead organ donors. In
the Rahier article, pancreas weight was
measured at autopsy, whereas in the cur-
rent study, population pancreas volumes
were used as the pancreas weight was not
available in the individuals from whom
the pancreas samples were available. The
large number of cases in both the Rahier
and the present study likely compensate
for the limitations of measurement of
b-cell mass in human autopsy studies.
Also in agreement with Rahier et al.
(3), we affirm that the increment in b-cell
mass with obesity is due to increased
numbers of cells rather than cell size.
The increase in b-cells in response to obe-
sity with no detectable increase in b-cell
replication in humans noted here is con-
sistent with the recent observation that
b-cell mass is adaptively increased in hu-
man pregnancy but without a detectable
increase in b-cell replication (18). Pre-
sumably these findings either reflect an
increase in b-cell formation in response
to obesity and pregnancy from sources
other than the duplication of existing
b-cells (so-called neogenesis) or an in-
crease in b-cell replication that is too
small to be detected. Alternatively, the in-
crease in the number of b-cells may occur
early in response to increasing obesity,
with no further increase once obesity is
established. We selected a wide range of
BMIs for the obese group to include indi-
viduals classified as overweight rather
than obese (BMI $27 kg/m2), but there
was still no detectable increase of b-cell
replication in individuals from the lower
BMI tertile of the obese group. Themajor-
ity of the b-cells observed to be replicat-
ing (64%) in the lean young group were
observed in only 2 of the 14 subjects.
Without those two cases, the average rep-
lication (0.030%) in the lean young group
was numerically similar to the other two
groups. Based on the few individuals in
which b-cell replication was detected,
even a very large number of additional
study subjects would be unlikely to result
Figure 2dFractional b-cell area (A), estimated pancreas parenchymal volume (B), and computed b-cell mass (C) in lean and obese nondiabetic
subjects. The pancreatic fractional b-cell area was;30% greater in the obese vs. the lean group (A). Estimated pancreas parenchymal volume (see
RESEARCH DESIGN AND METHODS) was ;15% greater in the obese vs. the lean subjects (B). In consequence, the computed mean b-cell mass was
;50% higher in obese subjects (0.8 g in lean and 1.2 g in obese) (C). However, there was no increase in mean individual b-cell size in obese
subjects (D).
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b-Cell mass with obesity and aging
in significant group differences. Given the
absence of lineage tracing in humans, it is
not possible at present to resolve the ori-
gins of newly forming b-cells in humans
in pregnancy and obesity.
b-Cell apoptosis is increased in hu-
mans with type 2 diabetes and this has
been ascribed to increased pancreatic fat
with obesity leading to “lipotoxicity” (4).
This hypothesis arose largely as a result of
the increased b-cell apoptosis present in
the absence of leptin signaling in a rodent
model of diabetes (19). However, al-
though fat accumulates in the pancreas
in humans with obesity, the impact of
this increased fat on induction of diabetes
in humans is not well established (5). It
has been reported that pancreatic fat is
negatively associated with b-cell function
in nondiabetic individuals but not in type
2 diabetes (20). However, there is no in-
crease inb-cell apoptosis even in the pres-
ence of marked obesity when pancreatic
fat is increased (5). Moreover, to our
knowledge, there are no reports of in-
creased pancreatic fat in humans with
type 2 diabetes compared with nondia-
betic individuals when matched for obe-
sity. On the contrary, one large study
reported no increase in pancreatic fat in
humans with type 2 diabetes (5). As dis-
cussed by Unger and Zhou (4), lipotoxic-
ity is based on the harmful partitioning of
fat from the relatively safe storage in adi-
pocytes compared with the relatively toxic
accumulation of lipids within the tissue in
question. It is plausible that fat accumu-
lates in and around islets in humans with
type 2 diabetes to a greater extent than in
comparably obese nondiabetic humans,
but this is yet to be established.
The remarkable preservation of b-cell
mass in humans with advanced age de-
spite marked loss of pancreatic acinar tis-
sue noted in the present studies is
consistent with one prior study in hu-
mans that reported a marginal decrease
in b-cell mass with aging (no significant
difference between the youngest and old-
est age-group studied) (3). Here we ex-
tend those observations by including
individuals to 100 years of age and eval-
uating b-cell turnover. There was no de-
tectable change in b-cell apoptosis
despite advanced age. Since it has also
been shown that fat relative to acinar tis-
sue accumulates in the pancreas with ad-
vanced age (5), apparent histologically in
the present studies (Fig. 1), it is again no-
table that there was no increase in b-cell
apoptosis despite advanced age.
With both obesity and advanced age,
we report an increased b-cell nuclear di-
ameter. Studies of the parathyroid gland
have indicated a relationship between
parathyroid hormone secretion and the
mean nuclear diameter of parathyroid
cells (21). The increase in mean b-cell nu-
clear diameter observed here with obesity
is consistent with a prior report and an
appreciation that daily insulin secretion is
increased inobesity (13).Glucose-stimulated
insulin secretion and insulin sensitivity
decline with aging, with the result that
fasting and postprandial glucose concen-
trations are increased (6). The net effect of
these changes with aging in nondiabetic
individuals is that insulin secretion is
adaptively increased at the higher blood
glucose levels (but not raised to levels con-
sidered diabetic) in both the fasting and
fed state, with the result that b-cell work-
load is increased through the 24-h cycle
consistent with the increased b-cell
nuclear diameter with aging reported
here. The extremely low frequency of
b-cell apoptosis in humans across all age-
groups is consistent with reports that in
health b-cells are long lived (22). Here
we extend this to include advancedold age.
As with all prior studies approaching
the question of b-cell mass and turnover
in humans, the current study has limita-
tions. In the present studies, we have re-
lied on population-based values obtained
by CT scan for pancreas volumes rather
than a direct measurement of pancreas
weight mass in the individuals from
whom the pancreas samples were ob-
tained. We also assumed that 1 cm3 of
pancreas weighs 1 g. A large number of
subjects were studied to develop the pop-
ulation pancreas data, being specifically
selected to encompass the age and BMI
range of the current study subjects. Al-
though the use of population pancreas
volumes is clearly a limitation, given the
retroperitoneal and locally adherent na-
ture of the human pancreas, measuring
the weight of pancreas resected at autopsy
is not without error. Autopsy studies here
are confined to the tail of the pancreas,
and the changes in pancreas volume are
calculated from population values ascer-
tained in a large radiological study, an ap-
proach that was validated in nonhuman
primates (7).
Another limitation of autopsy studies
is that changes in b-cell mass or turnover
may be present as a result of the final ill-
ness or postmortem. Tominimize this, we
sought to include cases where the course
of the final illness was relatively short and
the time between death and autopsy was
no longer than 12 h. The very low fre-
quency of TUNEL-positive b-cells pro-
vides reassurance that the quality of the
pancreas included was not only well pre-
served in appearance but also had under-
gone minimal postmortem autolysis. In
pancreas procured 24 h after death, we
have noted a high frequency of TUNEL in
Figure 3dCorrelation between b-cell mass and BMI in nondiabetic humans. There was a sig-
nificant positive correlation between b-cell mass and BMI.
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all cell types, consistent with postmortem
necrosis. The present studies did not in-
clude an obese elderly group. This was
partly by design since the planned hypoth-
eses required comparison between obese
and lean individuals (age matched), and
young and elderly individuals (BMI
matched). The lack of an obese elderly
group was also a practical issue as there
are relatively few elderly obese individu-
als in the Mayo autopsy registry, presum-
ably reflecting the impact of obesity on
life expectancy.
By definition, autopsy studies are
cross-sectional, introducing the possibil-
ity of confounding variables. For exam-
ple, individuals who live to advanced old
age are by definition a selected group
compared with those who die young.
Ideally, a cohort of individuals would be
studied throughout life to establish
changes in b-cell mass with aging. This
is currently not possible since it is still
not technically feasible to measure b-cell
mass in vivo, and if it was possible, the
longitudinal study to address the effects of
age on pancreas shown here would take
100 years to complete. Moreover that ap-
proach would still not permit evaluation
of b-cell turnover.
In conclusion, the mass and number
of b-cells is increased in humans with
obesity. Neither the timing of that in-
crease nor its origins are known. The
number and mass of b-cells are relatively
well preserved compared with the exo-
crine pancreas in humans despite ad-
vanced age. Neither obesity nor
advanced age in humans is characterized
by increased b-cell apoptosis.
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